COMPANY PROFILE

Xlumena

Explore full profile

Xlumena develops products that enable advanced image-guided endoscopic therapy

Mountain View, United StatesFounded 2008Biotech & Life Sciences

Valuation $50–100M Last recorded · 2015

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Xlumena

XLumena specializes in developing innovative medical devices, particularly for gastroenterology, aimed at improving patient outcomes and safety. The company operates in the healthcare sector, focusing on creating single-use medical instruments that reduce the risk of cross-contamination and infection. XLumena's primary clients include hospitals, clinics, and healthcare providers who require advanced, reliable, and safe medical tools. The business model revolves around the research, development, and sale of these specialized devices, generating revenue through direct sales and partnerships with healthcare institutions. By prioritizing patient-focused innovation, XLumena aims to set new standards in medical technology and patient care.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2008
Headquarters: Mountain View, United States
Employees: 3
Open positions: None listed
Dealroom signal: 25.7/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Gastroenterology, Medical Imaging, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Apr 2015	$75M	$75M	Boston Scientific	—
SERIES C✓Equity / VC	Dec 2013	$25M	$100M	Charter Life Sciences · Ascent Biomedical Ventures · Aperture Venture Partners · Prism Venture Management	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Xlumena website traffic

Latest recorded traffic for Xlumena is 0 monthly website visits.

Latest monthly visits0

Monthly website visitsJan 2020–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ALAlcrestaDeveloping and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases	Newton, United States	Acquired	108	$96M	$40M
EAEarlySightDeveloping a medical device to help doctors detect and treat eye diseases at an early-stage thanks to precise measurement of the eye condition	Geneva, Switzerland	Operational
ENEndoChoiceA platform-technology firm, provides devices, diagnostics and infection control for treating gastrointestinal diseases	Alpharetta, United States	Acquired
BMBiop MedicalCompact optical device enabling real-time cervical examination to support detection of lesions and cancer and guide biopsy decisions	Netanya, Israel	Operational
BTBiora TherapeuticsClinical laboratory services to provide physicians and patients with accurate, timely and state-of-the-art test results	San Diego, United States	Operational
ATAimmune TherapeuticsAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company	San Mateo, United States	Acquired
SPSynergy PharmaceuticalsWe’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients	New York City, United States	Operational
RBRedHill BiopharmaRedHill (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on proprietary drugs for gastrointestinal diseases	Raleigh, United States	Operational